Rapport Therapeutics Shares Close 2.7% Higher on Phase 2 Results Day
Photo: TokenPost
Rapport Therapeutics (RAPP) shares closed Tuesday at $29.37, up 2.7% from Monday, the day before the company announced topline Phase 2 results for its experimental drug RAP-219 in adults with acute mania associated with bipolar I disorder. The Tuesday close was recorded at 4 p.m. ET (20:00 UTC). Monday’s $28.60 close was 3.74% above the previous session’s $27.57 close. That gain preceded the trial announcement. The three-week trial enrolled 253 U.S. adults experiencing acute mania linked to bipolar I disorder. It used a randomized, double-blind, placebo-controlled design, with patients treated in an inpatient setting.
Source: TokenPost
